INGN Lifts Outlook, BCLI Awaits DSMB Review, TRVN To Report Data Next Month
INGN Lifts Outlook, BCLI Awaits DSMB Review, TRVN To Report Data Next Month
View ArticleRVNC Works It Out, ONCE Awaits Data, AKBA, VTAE Make Big Moves, TTPH Doused
RVNC Works It Out, ONCE Awaits Data, AKBA, VTAE Make Big Moves, TTPH Doused
View ArticleZafgen: Beloranib Granted Orphan Drug Designation In EU - Quick Facts
Zafgen: Beloranib Granted Orphan Drug Designation In EU - Quick Facts
View ArticleZafgen Says Patient in Beloranib Study Dies
Zafgen Says Patient in Beloranib Study Dies
View ArticleZafgen: FDA Puts Trial on Partial Hold After Patient Death
Zafgen: FDA Puts Trial on Partial Hold After Patient Death
View ArticleFDA Puts Zafgen Trial on Hold After Patient Death
FDA Puts Zafgen Trial on Hold After Patient Death
View ArticleZafgen Says Another Patient Dies in Beloranib Study
Zafgen Says Another Patient Dies in Beloranib Study
View ArticleZafgen Says a Second Patient Died in Beloranib Study
Zafgen Says a Second Patient Died in Beloranib Study
View ArticlePakistani Taliban Attack University, Killing 19
Pakistani Taliban Attack University, Killing 19
View ArticleSRPT's Anxious Wait To Continue, ZFGN Has Reason To Flaunt, OGXI Disappoints
SRPT's Anxious Wait To Continue, ZFGN Has Reason To Flaunt, OGXI Disappoints
View ArticleZafgen''s Beloranib Trial Shows Significant Improvements In Weight Loss
Zafgen''s Beloranib Trial Shows Significant Improvements In Weight Loss
View ArticleZafgen Suspends Development Of Beloranib; Shares Plunge More Than 40%
Zafgen Suspends Development Of Beloranib; Shares Plunge More Than 40%
View ArticleSCLN Withdraws From Auction Block, ZFGN Tumbles, Double Blessing For VRX
SCLN Withdraws From Auction Block, ZFGN Tumbles, Double Blessing For VRX
View ArticleINFI Turns Heads, ARDX Marches On, VYGR Cruises Ahead, ACRX Disappoints
INFI Turns Heads, ARDX Marches On, VYGR Cruises Ahead, ACRX Disappoints
View ArticleZFGN Awaits Data, SLDB Makes Solid Gains, RCKT On Fire, SGEN Snaps Up CASC
ZFGN Awaits Data, SLDB Makes Solid Gains, RCKT On Fire, SGEN Snaps Up CASC
View ArticleARRY's COLUMBUS Turns Heads, ZFGN On Course, MNOV UP 66% YTD
ARRY's COLUMBUS Turns Heads, ZFGN On Course, MNOV UP 66% YTD
View ArticleFDA Approves New HIV Drug, Mark Your Calendar For BHVN, Watch Out For ZFGN
FDA Approves New HIV Drug, Mark Your Calendar For BHVN, Watch Out For ZFGN
View Article
More Pages to Explore .....